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REMARKS BY JON SODERSTROM*
Senator Birch Bayh has made the most significant impact on the U.S. and
global economy of any individual who has ever come before and who lives
today, full stop. That’s an amazing accomplishment. We have heard about
all the legislative feats that he accomplished. We’ve heard about what an
amazing legislator, attorney, and public servant he was. But, there are very
few human beings who have had the impact on our economy that Senator
Bayh had. It’s an amazing accomplishment and something that we should be
in awe of.
I’m going to give you a few statistics. I’m not going to overwhelm you;
I’m going to bring it down to a personal level. I promised Kitty that I
wouldn’t cry. Because when I was thinking about this the other day, it’s
hard. If you knew Senator Bayh, he wore his emotions on his sleeve, and we
have cried together.
Here are just a couple statistics that should blow you away. The BayhDole Act1 unleashed the technologies that were being developed in
universities in a way that no one probably could have imagined. It was
immediate and it was dramatic. The year was 1980. Prior to 1980—and I
know because my entire career arc has followed the senator’s
accomplishments—I was at graduate school studying the economy and what
patents were doing, et cetera. At that time, the federal government, by law,
was the owner of all intellectual property created with federal dollars and, as
a result, it had created 28,000 patents.2 Less than 5 percent of those patents
had ever been licensed or commercialized, compared with 25 percent to 30
percent of the small number of federal patents for which the government had
allowed companies to retain title to the invention.3 That is “because the
government would only grant nonexclusive licenses to patents it owned,” so
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“a wall was erected between academic and corporate research.”4 Companies
refused to invest the significant time and resources needed to receive
regulatory approval in nascent technologies that could be simply copied by
others, especially foreign firms, obtaining the same nonexclusive license.
Research was often described in this period as being “contaminated” by
federal funding because of the government’s licensing policies.5 In spite of
the fact that a large portion of that was spent on the Department of Health
and Human Services and the National Institutes of Health, no drug could
trace its lineage to a patent license based on research that had been supported
by the federal government.6 That’s before Bayh-Dole.
From 1980 on, things changed. Universities became the owners of the
patents, and the reason was simple: Senator Bayh recognized that you needed
to put the intellectual property in the hands of the people who actually
invented it. Those are the people who understand it; those are the people who
are passionate about it; those are the people who had the perseverance. They
would be the ones who would drive things forward. Subsequent to the
passage of the law, over 12,000 new companies were started.7 Interestingly
enough, over 6000 of those companies still exist.8 Many of them are
household names that you would recognize, such as Genentech and Amgen,
just in the life sciences area. Importantly, 153 new drugs have been
discovered, have gone through the clinical development process, and are on
the market after receiving Food and Drug Administration (FDA) approval.9
I’m going to talk to you about one. I’m going to use it to show what
happened and why this law is so important. There was a scientist at Yale
University, where I’ve worked for many years now. His name was William
Prusoff. In the 1950s, he had this amazing insight about how to create new
types of drugs to combat infectious disease by interfering with the DNAsynthesis mechanism.10 He invented the very first antiviral drug,11 but no
one filed a patent. It was to cure a form of blindness that was caused through
a defect in a DNA mechanism.12 It never got commercialized; nobody cared
and nobody did anything with it.
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Now, we’re in 1984 and many of you here will remember what the crisis
of the 1980s was: AIDS. Nobody knew what it was or how it was
transmitted. It was a death sentence. If you got it, you were going to die.
The only question was when. There were no drugs to treat it because nobody
knew how it worked. Many academic medical centers, like my own,
mobilized resources to start to understand exactly how the virus was
transmitted and replicated and how it attacked the body’s immune system.
They started to try everything they could possibly think of to stop it. Nothing
worked.
Lo and behold, two scientists at Yale—Bill Prusoff and Tai-Shun Lin—
went into the freezer and found a compound called stavudine that had been
developed many years before but had not been commercialized.13 It had just
been distributed among academics.14 It had been developed by Jerome
Horowitz at the Karmanos Cancer Center in Detroit.15 He thought it would
be a cancer drug, but it failed.16 Inspired by Bill’s pioneering work in the
1950s on antiviral therapy for disease treatment, he and Dr. Lin decided to
try it to treat the AIDS virus.17 They discovered this was the first time any
chemical had ever killed the virus with this level of activity.18
There were a couple of problems, including that this was not a drug that
could be used on humans and that it was very difficult to make.19 Because
the two scientists had developed a relationship with Bristol Myers Squibb
(BMS) and the Bayh-Dole Act encouraged researchers to work with
companies to license patent rights for work they did, they approached BMS
and asked if they would be interested in working on the drug.20 BMS said
they would be interested if the scientists could solve those problems.21 Over
the next nine months to a year, they solved all of the problems.22 In 1984,
BMS took the drug, finished the preclinical development package, went to
the FDA, and got the first fast-track approval for this drug.23 It became
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known as Zerit.24 It was the very first effective medication against HIVAIDS. It also became the very first component of what became the AIDS
three-drug “cocktail.”25 With that, what was a death sentence became a
manageable disease. That’s amazing. That has saved millions of lives.
In 1980, when Senator Bayh was advocating for this change, he was doing
so because it just seemed like the right thing to do—to unleash the
entrepreneurial spirit behind this intellectual property. What he didn’t realize
was the impact it was going to have on individuals all over the world. This
drug, Zerit, which has now been followed by even better variations, ended
up stemming the AIDS crisis in Africa, eastern Asia, and other parts of the
developed world.26 This was a miracle. None of this would have been
possible without the Bayh-Dole Act.
Subsequent to that, the Bayh-Dole Act has created about a trillion dollars’
worth of economic activity and 5.8 million jobs.27 Think about those
statistics for a minute. This is incredible for a small piece of legislation for
which he is hardly even recognized. Everybody knows about Senator Bayh’s
work on various amendments to the Constitution, which was great. But this
Act changed lives, and I’m one of them. Thank you.
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